We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: Cost-Effectiveness
MedXY News
EnglishTag

Cost-Effectiveness

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Cost-effectiveness of Robotic Versus Open Pancreatoduodenectomy: Insights from the DIPLOMA-2 Multicenter Randomized Trial
General SurgeryCost-Effectivenessquality-adjusted life years

Cost-effectiveness of Robotic Versus Open Pancreatoduodenectomy: Insights from the DIPLOMA-2 Multicenter Randomized Trial

By MedXY|Aug 17, 2026

This randomized trial analysis compares the costs and quality-adjusted life years of robotic versus open pancreatoduodenectomy, revealing no significant cost differences but a lower probability that robotic surgery is cost-effective at six

Cost-Effectiveness Analysis of Menopausal Hormone Therapy: Integrating Risk-Benefit Profiles and Economic Models
Clinical Updatescardiovascular disease
Cost-Effectiveness

Cost-Effectiveness Analysis of Menopausal Hormone Therapy: Integrating Risk-Benefit Profiles and Economic Models

By MedXY|Aug 18, 2026

This review synthesizes current evidence on menopausal hormone therapy’s cost-effectiveness, highlighting findings from a 2026 Markov model analysis and contextualizing with pivotal studies on health outcomes and economic implications

Approved Monoclonal Antibody Therapies for Hidradenitis Suppurativa: Efficacy, Safety, and Economic Assessments
Clinical UpdatesbiologicsCost-Effectiveness

Approved Monoclonal Antibody Therapies for Hidradenitis Suppurativa: Efficacy, Safety, and Economic Assessments

By MedXY|Aug 11, 2026

This review synthesizes current evidence on adalimumab, secukinumab, and bimekizumab for moderate-to-severe hidradenitis suppurativa, emphasizing clinical efficacy, safety, mechanistic insights, and cost-effectiveness across diverse health

Cost-Effectiveness of Perioperative Pembrolizumab in Head and Neck Cancer: Impact of PD-L1 Expression Levels
newsCost-Effectivenessimmunotherapy

Cost-Effectiveness of Perioperative Pembrolizumab in Head and Neck Cancer: Impact of PD-L1 Expression Levels

By MedXY|Aug 11, 2026

The addition of perioperative pembrolizumab to standard care improves event-free survival in locally advanced head and neck squamous cell carcinoma, with cost-effectiveness dependent on PD-L1 combined positive score.

Cost-Effectiveness of Oral Nicotinamide for Keratinocyte Carcinoma Prevention: A Clinical and Economic Review
Clinical UpdatesCost-Effectivenesskeratinocyte carcinoma

Cost-Effectiveness of Oral Nicotinamide for Keratinocyte Carcinoma Prevention: A Clinical and Economic Review

By MedXY|Jul 30, 2026

Oral nicotinamide reduces keratinocyte carcinoma incidence in high-risk individuals, providing significant cost savings and quality-adjusted life-year gains, supporting its role as a cost-effective preventive strategy.

Quality, Cost, and Timeliness of Cancer Treatment in Medicare Advantage Versus Traditional Medicare: An Evidence-Based Review
Clinical Updatescancer treatmentCost-Effectiveness

Quality, Cost, and Timeliness of Cancer Treatment in Medicare Advantage Versus Traditional Medicare: An Evidence-Based Review

By MedXY|Jul 17, 2026

Medicare Advantage beneficiaries with cancer receive guideline-concordant treatment similarly to Traditional Medicare enrollees but at lower costs and comparable timeliness, highlighting implications for healthcare policy and cost-effective

Evaluating the Economic Impact of Enhanced Primary Youth Mental Health Services: Insights from the ACCESS Open Minds Study
newscommunity servicesCost-Effectiveness

Evaluating the Economic Impact of Enhanced Primary Youth Mental Health Services: Insights from the ACCESS Open Minds Study

By MedXY|Jul 14, 2026

A retrospective cohort study of ACCESS Open Minds in Canada demonstrates significant cost savings and improved service utilization in youth mental health care through enhanced, community-based services.

First Trimester Screening for Preterm Preeclampsia in the United Kingdom: Evaluating the Cost-Effectiveness of the FMF Strategy versus NICE Guidelines
Clinical UpdatesCost-Effectivenessfirst trimester screening

First Trimester Screening for Preterm Preeclampsia in the United Kingdom: Evaluating the Cost-Effectiveness of the FMF Strategy versus NICE Guidelines

By MedXY|Jul 4, 2026

This review synthesizes evidence on the cost-effectiveness of the FMF first-trimester screening strategy for preterm preeclampsia in the UK compared to NICE recommendations, highlighting clinical efficacy, economic benefits, and implication

Cost-effectiveness of Pembrolizumab for FIGO 2014 Stage III-IVA Cervical Cancer in the United States
newsCost-Effectivenesspembrolizumab

Cost-effectiveness of Pembrolizumab for FIGO 2014 Stage III-IVA Cervical Cancer in the United States

By MedXY|Aug 18, 2026

Pembrolizumab plus chemoradiotherapy improved survival and quality-adjusted survival for FIGO 2014 stage III-IVA cervical cancer and was projected to be cost-effective in the U.S. at a $150,000/QALY threshold.

Is Semaglutide Worth the Cost? Evaluating the Economic Reality of GLP-1s for Heart Disease Prevention
Cardiologycardiovascular diseaseCost-Effectiveness

Is Semaglutide Worth the Cost? Evaluating the Economic Reality of GLP-1s for Heart Disease Prevention

By MedXY|Mar 20, 2026

A comprehensive simulation study evaluates the cost-effectiveness of semaglutide for secondary cardiovascular prevention in US adults without diabetes, finding significant health benefits but highlighting the need for price reductions to en

Semaglutide for Secondary CVD Prevention: Evaluating the Price of Clinical Success
Cardiologycardiovascular diseaseCost-Effectiveness

Semaglutide for Secondary CVD Prevention: Evaluating the Price of Clinical Success

By MedXY|Feb 5, 2026

A simulation study reveals that while semaglutide significantly reduces cardiovascular events in adults with obesity, its current cost exceeds traditional cost-effectiveness thresholds, requiring an 18% price reduction for broader economic

Cycling into Relief: The CLEAT Trial Validates Community-Based Exercise for Hip Osteoarthritis
newsclinical trialCost-Effectiveness

Cycling into Relief: The CLEAT Trial Validates Community-Based Exercise for Hip Osteoarthritis

By MedXY|Jan 13, 2026

The CLEAT trial demonstrates that an 8-week cycling and education program (CHAIN) significantly improves function in hip osteoarthritis compared to usual physiotherapy. Despite falling just short of the clinical importance threshold, its hi

Ten-Year TOPKAT Follow-up: Partial (Unicompartmental) Knee Replacement Matches Total Replacement Clinically and Is More Cost-Effective
newsCost-Effectivenesstotal knee replacement

Ten-Year TOPKAT Follow-up: Partial (Unicompartmental) Knee Replacement Matches Total Replacement Clinically and Is More Cost-Effective

By MedXY|Dec 1, 2025

The 10-year TOPKAT randomized trial found no clinically important difference in Oxford Knee Score between partial (PKR) and total knee replacement (TKR) for medial compartment osteoarthritis, similar revision/reoperation rates, and cost-eff

Screening Children and Young Adults for Familial Hypercholesterolemia: Clinically Helpful but Not Cost‑Effective
CardiologyCost-EffectivenessHypercholesterolemia

Screening Children and Young Adults for Familial Hypercholesterolemia: Clinically Helpful but Not Cost‑Effective

By MedXY|Nov 10, 2025

A modeling study found that sequential population screening for familial hypercholesterolemia (FH) at ages 10 or 18 is clinically effective but not cost‑effective versus usual care, unless follow-up monitoring and lifestyle interventions fo

Evaluating the Impact and Economics of Home Automated External Defibrillators: Insights from the CARES Registry
Cardiologycardiac arrestCost-Effectiveness

Evaluating the Impact and Economics of Home Automated External Defibrillators: Insights from the CARES Registry

By MedXY|Oct 29, 2025

AEDs improve survival in in-home cardiac arrests with shockable rhythms but are not cost-effective for widespread private home use at current prices and incidence rates, per a large US cohort study using CARES data.

Evaluating the Cost-Effectiveness of Early In-Bed Cycling Plus Routine Physiotherapy in Mechanically Ventilated ICU Patients: Insights from the CYCLE Trial
Critical CareCost-Effectivenessmechanical ventilation

Evaluating the Cost-Effectiveness of Early In-Bed Cycling Plus Routine Physiotherapy in Mechanically Ventilated ICU Patients: Insights from the CYCLE Trial

By MedXY|Oct 27, 2025

This economic evaluation from the CYCLE randomized trial found no significant cost or quality-adjusted life-year benefit by adding early in-bed cycling to usual physiotherapy for ICU patients on mechanical ventilation, underscoring a need f

Cost-Effectiveness of Mailed HPV Self-Testing Kits for Cervical Cancer Screening Across Diverse Screening Histories
Clinical UpdatesCost-Effectiveness

Cost-Effectiveness of Mailed HPV Self-Testing Kits for Cervical Cancer Screening Across Diverse Screening Histories

By MedXY|Oct 6, 2025

Economic evaluation shows direct mailing of HPV self-sampling kits improves cervical cancer screening completion and is cost-effective among varied screening history groups in a US healthcare system, with budget benefits over time.

Evolving Trends and Economic Implications of Breast Cancer Screening in Older US Women: Navigating Value and Cost
OB/GYN & Women's Healthbreast cancerCost-Effectiveness

Evolving Trends and Economic Implications of Breast Cancer Screening in Older US Women: Navigating Value and Cost

By MedXY|Oct 6, 2025

Breast cancer screening among older US women shows stable use but rising costs driven by low-value technologies; optimizing screening strategies could enhance value and reduce expenditure.

Novel Contrast-Derived Indices of Coronary Microvascular Function: Potential Clinical and Cost Benefits
CardiologyCost-Effectiveness

Novel Contrast-Derived Indices of Coronary Microvascular Function: Potential Clinical and Cost Benefits

By MedXY|Oct 2, 2025

This study evaluates new contrast-derived indices of coronary microvascular function, highlighting their diagnostic potential and cost-effectiveness compared to traditional adenosine testing.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities